Actinium Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 9 of 9 Posts
Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity
Article By: Jason Napodano Monday, June 12, 2017 1:41 PM EDT
BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care.
In this article: ATNM
Read
EMA Gives Thumbs-Up To Actinium's Phase 3 SIERRA Program
Article By: Jason Napodano Tuesday, March 21, 2017 10:07 AM EDT
Today's news is very positive for Actinium. Enrollment in SIERRA continues on plan and there are DMC updates expected around the middle of the year and again potentially at year end.
In this article: ATNM
Read
Actinium Offers Shareholders Several Interesting Near-Term Catalysts
Article By: Jason Napodano Friday, February 24, 2017 12:50 PM EDT
Shares of ATNM have performed nicely over the past month, driven by the achievement of several milestones, including the hiring of a new Chief Medical Officer and initiation of a new clinical trial with Actimab-M for multiple ATNM​myeloma.
In this article: ATNM Also: SGEN
Read
What Does SGEN's Clinical Hold On CD33A Mean For Actinium?
Article By: Jason Napodano Wednesday, January 4, 2017 5:35 PM EDT
The Seattle Genetic news to temporarily halt clinical work in some studies with CD33A is not a negative reflection on Actinium. It might, in fact, instead be an opportunity.
In this article: SGEN, ATNM
Read
ASH Abstract Confirms Positive Outlook For Actinium's Actimab-A
Article By: Jason Napodano Wednesday, November 9, 2016 3:46 PM EDT
Actinium now has a validated safe and effective treatment for elderly patients with newly-diagnosed AML progressing in a Phase 2 clinical study. Importantly, the Phase 1 data shows that at 2 µCi/kg, the CR rate was 50%
In this article: ATNM
Read
Comparing Actinium's Actimab-A To Seattle Genetics' SGN-CD33A
Article By: Jason Napodano Tuesday, October 11, 2016 5:40 PM EDT
Several biopharma companies are working on therapeutic agents for AML that target CD33, including Amgen, Bayer, Boehringer Ingelheim, and J&J. However, only Actinium and Seattle Genetics (SGEN) have progressed beyond Phase 1 studies.
In this article: ATNM, SGEN
Read
Actinium Announces Proposed Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Wednesday, September 28, 2016 9:03 PM EDT
Actinium Pharmaceuticals, Inc., announced today that it intends to offer shares of its common stock in an underwritten public offering.
In this article: ATNM
Read
E Actinium Pharmaceuticals Inc. Submits Proposal To FDA For Phase 3 Blood Cancer Trial
Article By: Terry Chrisomalis Wednesday, July 15, 2015 11:42 AM EDT
Actinium files phase 3 pre-IND meeting for its blood cancer trial to treat patients with its lomab-b drug candidate .
In this article: ATNM
Read
ATNM Submits CMC Meeting Request To FDA For Iomab-B; NBIX Announces Oral Presentation Of NBI-77860 Clinical Trial Data
Article By: BioMedReports Wednesday, January 21, 2015 9:18 AM EDT
ATNM announced that it has submitted a request for a CMC meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug. NBIX announced the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860.
In this article: ATNM, NBIX
Read
1 to 9 of 9 Posts